Roivant Sciences heads into a pivotal stretch — earnings due May 29 — with short sellers rebuilding positions, executives selling stock, and options traders the most bullish they've been in months.
The most consequential shift in positioning is in short interest. It has climbed to 5.25% of the free float, up from roughly 4.4% at the start of April — a rise of nearly 20% over six weeks. The sharpest leg came this week: shorts added around 6.5% in a single five-day window, pushing the SI back to levels last seen during a brief spike on April 23. That acceleration arrived even as the stock slipped 4% on the week to $28.21, which makes the rebuild look conviction-driven rather than tactical. The ORTEX short score has tracked the move, rising from below 40 at the start of the month to 42.8 now, though it remains in moderate rather than extreme territory. Borrow costs complicate the picture somewhat: they dropped sharply to just 0.16% APR on May 19 — a 61% fall on the week — after running at around 0.41% for most of the prior month. That signals no friction in adding new short exposure. Availability is exceptionally loose at over 3,000% — meaning the lending pool dwarfs current demand — so the recent short build reflects bearish conviction, not a forced squeeze dynamic.
Options positioning, however, tells the opposite story. The put/call ratio has fallen to 0.56, well below its 20-day average of 0.83. The z-score of -1.53 places this reading among the most call-heavy of the past year. Earlier in May the PCR briefly touched 1.20 — the 52-week high — suggesting a sharp rotation from hedging to directional upside bets in just a fortnight. Ahead of the May 29 print, options traders are overwhelmingly positioned for the stock to move higher, even as short sellers rebuild.
The Street is firmly in the bulls' camp. Every recent analyst action has been a target raise, with no downgrades in the visible history. Piper Sandler made the most striking move in April, lifting its target from $22 to $40 while maintaining Overweight — a near-doubling that suggests the firm materially re-rated the risk/reward following clinical developments. Citigroup and Goldman Sachs both raised targets around the February earnings, and the consensus price target now stands at $36.13 against a current price of $28.21, implying roughly 28% upside from here. The bull case centres on VTAMA's commercial traction in plaque psoriasis and a Phase 3 Batoclimab readout in NIU expected in the second half of 2026. Bears point to the company's pre-profitability status — the P/E and EV/EBITDA multiples are both deeply negative, and the earnings yield is modestly negative at -0.04 — meaning the entire thesis rests on pipeline delivery.
Insider activity cuts against the optimism on the Street. The CEO, Matthew Gline, sold nearly 290,000 shares at $29.16 on April 16 for proceeds of $8.4 million. He sold again on March 31 — a further 304,000 shares at $27.70, another $8.4 million. Co-President Eric Venker followed with a 200,000-share sale at $29.59 in late April. President/CIO Mayukh Sukhatme also trimmed across late March. In aggregate, insiders have been net sellers of more than $180 million in value over the past 90 days. These disposals are largely on a schedule, but the scale is notable: multiple C-suite executives selling simultaneously near the stock's recent highs, just as the pipeline catalyst window approaches.
Institutional flows are more mixed. FMR (Fidelity) added 12.2 million shares in Q1, becoming the second-largest holder at nearly 11% of shares. BlackRock added 3.1 million shares and UBS Asset Management added 3.9 million. In contrast, Vivek Ramaswamy — a Roivant co-founder — trimmed by 8.2 million shares in Q1, and QVT Financial reduced its stake.
The setup into May 29 is therefore one of competing signals: options traders leaning call, analysts lifting targets, large-scale institutional buying — all while shorts rebuild and insiders lock in gains at $28–$30. The one prior earnings reaction on record showed a modest -2.2% move the next day followed by a recovery to flat over five days — a subdued template for a stock where the bigger catalyst is a Phase 3 readout months away, not the quarterly print itself. What to watch is whether the short rebuild accelerates further into the earnings date or reverses ahead of it, and what tone management takes on the Batoclimab timeline on the call.
See the live data behind this article on ORTEX.
Open ROIV on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
